Combined with anti-Nogo-A antibody treatment, BDNF did not compensate the extra deleterious motor effect caused by large size cervical cord hemisection in adult macaques.
Details
Serval ID
serval:BIB_6044F1D482DC
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Combined with anti-Nogo-A antibody treatment, BDNF did not compensate the extra deleterious motor effect caused by large size cervical cord hemisection in adult macaques.
Journal
CNS neuroscience & therapeutics
ISSN
1755-5949 (Electronic)
ISSN-L
1755-5930
Publication state
Published
Issued date
02/2020
Peer-reviewed
Oui
Volume
26
Number
2
Pages
260-269
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Abstract
In spinal cord injured adult mammals, neutralizing the neurite growth inhibitor Nogo-A with antibodies promotes axonal regeneration and functional recovery, although axonal regeneration is limited in length. Neurotrophic factors such as BDNF stimulate neurite outgrowth and protect axotomized neurons. Can the effects obtained by neutralizing Nogo-A, inducing an environment favorable for axonal sprouting, be strengthened by adding BDNF? A unilateral incomplete hemicord lesion at C7 level interrupted the main corticospinal component in three groups of adult macaque monkeys: control monkeys (n = 6), anti-Nogo-A antibody-treated monkeys (n = 7), and anti-Nogo-A antibody and BDNF-treated monkeys (n = 5). The functional recovery of manual dexterity was significantly different between the 3 groups of monkeys, the lowest in the control group. Whereas the anti-Nogo-A antibody-treated animals returned to manual dexterity performances close to prelesion ones, irrespective of lesion size, both the control and the anti-Nogo-A/BDNF animals presented a limited functional recovery. In the control group, the limited spontaneous functional recovery depended on lesion size, a dependence absent in the combined treatment group (anti-Nogo-A antibody and BDNF). The functional recovery in the latter group was significantly lower than in anti-Nogo-A antibody-treated monkeys, although the lesion was larger in three out of the five monkeys in the combined treatment group.
Keywords
Animals, Antibodies, Blocking/therapeutic use, Axons, Brain-Derived Neurotrophic Factor/therapeutic use, Cervical Cord/injuries, Hand, Macaca fascicularis, Male, Motor Skills, Movement Disorders/drug therapy, Movement Disorders/etiology, Nerve Regeneration, Nogo Proteins/antagonists & inhibitors, Psychomotor Performance/drug effects, Recovery of Function, Spinal Cord Injuries/complications, Spinal Cord Injuries/drug therapy, Nogo-A antibody therapy, brain-derived neurotrophic factor, hand, manual dexterity, motor control, nonhuman primates, spinal cord injury
Pubmed
Web of science
Open Access
Yes
Create date
11/09/2019 14:05
Last modification date
12/01/2022 7:10